CJC-1295 (a GHRH analog) and Ipamorelin (a selective ghrelin receptor agonist) are often combined to stimulate growth hormone release
through complementary mechanisms. Together, they enhance natural GH and IGF-1 production, supporting recovery, fat loss, and lean
muscle development.
Key Benefits
• Synergistic GH Release: Stronger and more sustained growth hormone pulses.
• Lean Muscle Growth: Supports protein synthesis and recovery.
• Fat Reduction: Promotes lipolysis and metabolic balance.
• Anti-Aging Support: May improve sleep, skin, and energy levels.
Clinical Findings
• CJC-1295: Shown to extend half-life of GHRH, leading to sustained GH elevation.
• Ipamorelin: Highly selective GHRP with minimal cortisol/prolactin impact.
• Combination: Research suggests enhanced GH and IGF-1 secretion when used together.
Safety & Tolerability
• Generally well tolerated in studies.
• Possible mild side effects: flushing, headache, injection site irritation, transient hunger.
• Long-term safety data limited.
Dosing
• Research protocols (variable):
– CJC-1295: 100–200 mcg daily or 2–3x weekly (DAC versions last longer).
– Ipamorelin: 100–300 mcg daily or 2–3x daily depending on goals.
For research and informational purposes only – not for medical use.




Reviews
There are no reviews yet.